105 related articles for article (PubMed ID: 26459727)
1. Effects of epidermal growth factor receptor inhibitor on proliferative cholangitis in hepatolithiasis.
Yang Q; Zhou Y; Li FY; Mao H; Shrestha A; Ma WJ; Cheng NS; Zhang W
Hepatobiliary Pancreat Dis Int; 2015 Oct; 14(5):509-15. PubMed ID: 26459727
[TBL] [Abstract][Full Text] [Related]
2. Proliferating cell nuclear antigen shRNA treatment attenuates chronic proliferative cholangitis in rats.
Li FY; Cheng NS; Cheng JQ; Mao H; Zhou Y; Jiang LS; Li N
J Gastroenterol Hepatol; 2009 May; 24(5):920-6. PubMed ID: 19032457
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor as a target for anti-proliferative treatment of proliferative cholangitis in hepatolithiasis.
Li F; Zhou Y; Cheng N; Mao H; Jiang L; Li N; Li Q; de Jong MC; Pawlik TM
J Surg Res; 2011 Mar; 166(1):87-94. PubMed ID: 20097367
[TBL] [Abstract][Full Text] [Related]
4. Significance of controlling chronic proliferative cholangitis in the treatment of hepatolithiasis.
Li FY; Cheng NS; Mao H; Jiang LS; Cheng JQ; Li QS; Munireddy S
World J Surg; 2009 Oct; 33(10):2155-60. PubMed ID: 19641953
[TBL] [Abstract][Full Text] [Related]
5. EGFR monoclonal antibody panitumumab inhibits chronic proliferative cholangitis by downregulating EGFR.
Liu SH; Chen XF; Xie ZB; Zhou J
Int J Mol Med; 2019 Jul; 44(1):79-88. PubMed ID: 31115490
[TBL] [Abstract][Full Text] [Related]
6. Effects of epidermal growth factor receptor inhibitor genistein on proliferative cholangitis in rats.
Jiang L; Jiang LS; Yan LN; Li FY; Wang W; Cheng NS; Wen TF
J Surg Res; 2010 Jul; 162(1):59-67. PubMed ID: 19665144
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of percutaneous transhepatic cholangioscopic lithotomy for hepatolithiasis.
Huang MH; Chen CH; Yang JC; Yang CC; Yeh YH; Chou DA; Mo LR; Yueh SK; Nien CK
Am J Gastroenterol; 2003 Dec; 98(12):2655-62. PubMed ID: 14687812
[TBL] [Abstract][Full Text] [Related]
8. Practical value of applying cdc2 kinase shRNA to chronic proliferative cholangitis in treatment of hepatolithiasis.
Li FY; Cheng NS; Cheng JQ; Mao H; Jiang LS; Li QS; Zhou Y
Hepatogastroenterology; 2009; 56(94-95):1477-82. PubMed ID: 19950813
[TBL] [Abstract][Full Text] [Related]
9. Biliary antibiotics irrigation for E. coli-induced chronic proliferative cholangitis and hepatolithiasis: A pathophysiological study in rabbits.
Ma WJ; Wu ZR; Yang Q; Hu HJ; Wang JK; Shi YJ; Li FY; Cheng NS
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):356-367. PubMed ID: 31420296
[TBL] [Abstract][Full Text] [Related]
10. Suppression of proliferative cholangitis by E2F decoy oligodeoxynucleotide.
Yoshida M; Yamamoto N; Nitta T; Uehara T; Terao R; Hatano E; Iimuro Y; Yamaoka Y
J Surg Res; 2002 Feb; 102(2):95-101. PubMed ID: 11796004
[TBL] [Abstract][Full Text] [Related]
11. Effective Treatment of Chronic Proliferative Cholangitis by Local Gentamicin Infusion in Rabbits.
Yang Q; Wu Z; Liu F; Wang J; Ma W; Hu H; Li F; Pan Q
Biomed Res Int; 2018; 2018():6751952. PubMed ID: 30140699
[TBL] [Abstract][Full Text] [Related]
12. Treatment of chronic proliferative cholangitis with c-myc shRNA.
Li FY; Cheng NS; Cheng JQ; Mao H; Jiang LS; Li N; He S
World J Gastroenterol; 2009 Jan; 15(1):95-101. PubMed ID: 19115473
[TBL] [Abstract][Full Text] [Related]
13. Proliferating cell nuclear antigen expression in peribiliary glands of stone-containing intrahepatic bile ducts.
Lee KT; Sheen PC
Dig Dis Sci; 1999 Nov; 44(11):2251-6. PubMed ID: 10573370
[TBL] [Abstract][Full Text] [Related]
14. Down stream involvement of the bile duct in hepatolithiasis.
Lu S; Yan L; Rao L; Xia T; Gou J; Zhang S; Lei S
Chin Med J (Engl); 2002 Jan; 115(1):62-4. PubMed ID: 11930661
[TBL] [Abstract][Full Text] [Related]
15. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib for non-small cell lung cancer patients with liver cirrhosis.
Kim YH; Mio T; Mishima M
Intern Med; 2009; 48(18):1677-9. PubMed ID: 19755773
[TBL] [Abstract][Full Text] [Related]
17. Peroral cholangioscopic treatment of hepatolithiasis: Long-term results.
Okugawa T; Tsuyuguchi T; K C S; Ando T; Ishihara T; Yamaguchi T; Yugi H; Saisho H
Gastrointest Endosc; 2002 Sep; 56(3):366-71. PubMed ID: 12196774
[TBL] [Abstract][Full Text] [Related]
18. Macrophages and derived-TNF-α promote lipopolysaccharide-induced upregulation of endogenous β-glucuronidase in the epithelial cells of the bile duct: A possible facilitator of hepatolithiasis formation.
Yang Y; Wang Y; Wang C; Wu S; Yao D
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102062. PubMed ID: 36473630
[TBL] [Abstract][Full Text] [Related]
19. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
[TBL] [Abstract][Full Text] [Related]
20. The distribution of secretory immunoglobulin A in the intrahepatic biliary epithelium of patients with hepatolithiasis.
Hamba H; Kinoshita H; Hirohashi K; Kubo S; Fujio N
Surg Today; 1994; 24(9):849-51. PubMed ID: 7865966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
